Julian Rydzek
Overview
Explore the profile of Julian Rydzek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
531
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gudipati V, Rydzek J, Doel-Perez I, Goncalves V, Scharf L, Konigsberger S, et al.
Nat Immunol
. 2020 Jul;
21(8):848-856.
PMID: 32632291
Rational design of chimeric antigen receptors (CARs) with optimized anticancer performance mandates detailed knowledge of how CARs engage tumor antigens and how antigen engagement triggers activation. We analyzed CAR-mediated antigen...
2.
Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, et al.
Sci Transl Med
. 2019 Jul;
11(499).
PMID: 31270272
Immunotherapy with chimeric antigen receptor (CAR)-engineered T cells can be effective against advanced malignancies. CAR T cells are "living drugs" that require technologies to enable physicians (and patients) to maintain...
3.
Rydzek J, Nerreter T, Peng H, Jutz S, Leitner J, Steinberger P, et al.
Mol Ther
. 2018 Dec;
27(2):287-299.
PMID: 30573301
Chimeric antigen receptor (CAR)-T cell immunotherapy is under intense preclinical and clinical investigation, and it involves a rapidly increasing portfolio of novel target antigens and CAR designs. We established a...
4.
Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Briones Meijide J, et al.
Leukemia
. 2018 Feb;
32(5):1168-1179.
PMID: 29472720
FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed on normal hematopoietic stem and progenitor cells (HSC) and retained on malignant blasts in acute myeloid leukemia (AML). We engineered...
5.
Gogishvili T, Danhof S, Prommersberger S, Rydzek J, Schreder M, Brede C, et al.
Blood
. 2017 Nov;
130(26):2838-2847.
PMID: 29089311
SLAMF7 is under intense investigation as a target for immunotherapy in multiple myeloma. In this study, we redirected the specificity of T cells to SLAMF7 through expression of a chimeric...